Diverse studies revealed that the expression of immune-checkpoints (i.e., CTLA-4, PD-1 and PD-L1) and cytolytic activity markers (i.e., GZMA and PFR1) are important to determine the functional status of local anti-tumor immune response (Rooney et al., 2015; Sharma and Allison, 2015; Charoentong et al., 2017; Cogdill et al., 2017; Nishino et al., 2017; Narayanan et al., 2018; Thorsson et al., 2018; He and Xu, 2020). This evidence concerns the gene PDCD1 and neoplasm.